Enzyme redesign guided by cancer-derived IDH1 mutations.

Area of Science:

• Biocatalysis and enzyme engineering
• Metabolic engineering and synthetic biology
• Cancer genomics and enzyme function

Background:

• Enzyme mutations can lead to novel catalytic activities (neomorphism), observed in cancer.
• Isocitrate dehydrogenases (IDH) mutations are prevalent in certain cancers, altering their function.
• Homoisocitrate dehydrogenases (hIDH) are related enzymes with distinct substrate specificities.

Purpose of the Study:

• To engineer homoisocitrate dehydrogenases with neomorphic activity inspired by cancer mutations.
• To create biocatalysts for the production of (R)-2-hydroxyadipate, a precursor to adipic acid.
• To demonstrate enzyme redesign principles using cancer genomics insights.

Main Methods:

• Site-directed mutagenesis was used to introduce cancer-associated IDH mutations into hIDH.
• Homologous residues in the active sites of hIDH were targeted for mutation.
• Enzyme activity assays were performed to confirm the novel catalytic function.

Main Results:

• Engineered hIDH enzymes successfully catalyzed the conversion of 2-oxoadipate to (R)-2-hydroxyadipate.
• The neomorphic activity mimics a key step in adipic acid biosynthesis.
• This demonstrates successful enzyme redesign through rational mutation based on cancer data.

Conclusions:

• Cancer-associated mutations can be repurposed for beneficial enzyme redesign.
• Engineered hIDH provides a biocatalytic route for adipic acid production.
• This study exemplifies the translation of cancer genome insights into practical biotechnology.